Polypyridylruthenium(II) complexes exert anti-schistosome activity and inhibit parasite acetylcholinesterases

BACKGROUND: Schistosomiasis affects over 200 million people and there are concerns whether the current chemotherapeutic control strategy (periodic mass drug administration with praziquantel (PZQ)—the only licenced anti-schistosome compound) is sustainable, necessitating the development of new drugs....

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:PLoS Negl Trop Dis
Autores principales: Sundaraneedi, Madhu K., Tedla, Bemnet A., Eichenberger, Ramon M., Becker, Luke, Pickering, Darren, Smout, Michael J., Rajan, Siji, Wangchuk, Phurpa, Keene, F. Richard, Loukas, Alex, Collins, J. Grant, Pearson, Mark S.
Formato: Artigo
Lenguaje:Inglês
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5746282/
https://ncbi.nlm.nih.gov/pubmed/29240773
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pntd.0006134
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares